- R&D
Sionna Therapeutics Targets $156 Million in IPO to Advance Cystic Fibrosis Research
Sionna Therapeutics, a biotechnology firm headquartered in Waltham, Massachusetts, is preparing to raise up to $156 million through an initial public offering (IPO) as...Oculis’ Phase 2 Study Explores OCS-05 for Optic Nerve Inflammation
A phase 2 clinical trial has assessed the effectiveness and safety of OCS-05, a peptidomimetic small molecule developed by Oculis, for patients with optic...Research finds Merck’s treatment of lung disease can lower chance of death
Mohsin Riaz - 0Merck has released that its drug, Winrevair, reduced the risk of death in patients suffering from a rare condition that causes high blood pressure...GSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval in Younger Adults
Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader...
- Clinical
Bristol Myers Cuts Off Allergy Asset In Spite of Phase 3 Victory
Bristol Myers Squibb has persisted with its aggressive cost-reduction strategy, abandoning plans to market a competitor to Dupixent despite achieving its phase 3 objectives...Leap Therapeutics Shifts Focus to Colorectal Cancer After Mixed Phase 2b Trial Results
Leap Therapeutics has decided to redirect its efforts towards colorectal cancer following mixed results from a midstage trial of its anti-DKK1 antibody, sirexatamab. The...InnoCare and Keymed License Ex-China Rights for Bispecific to RTW-Backed Biotech in $520M Agreement
Chinese biotechs InnoCare Pharma and KeyMed Biosciences have licensed the international rights for their clinical-stage bispecific antibody, ICP-B02 (also known as CM355), to Prolium...Disc Medicine Refines Trial Design for EPP Drug, Targets Accelerated FDA Approval
Disc Medicine has finalized the design for its confirmatory trial of bitopertin, a drug candidate aimed at addressing a rare blood disorder, erythropoietic protoporphyria...
- Commercial
Biogen Secures Ex-U.S. Rights to Dravet Syndrome Treatment
Biogen has bolstered its research and development efforts by securing an agreement with Stoke Therapeutics for the ex-U.S. rights to zorevunersen, a treatment candidate...Former Inizio Evoke Executives Launch Flex Marketing
A group of former executives from health communications firm Inizio Evoke have launched Flex Marketing, a new independent agency catering to pharmaceutical, biotech, medtech,...Abcuro Secures $200 Million to Advance Ulviprubart for Inclusion Body Myositis Treatment
Abcuro, a biotechnology company backed by Sanofi, has secured $200 million in Series C funding to advance its anti-KLRG1 antibody, ulviprubart, through a phase...
- Technology
Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...AI Firm Formation Bags $372 Series D Funding
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was able to secure a remarkable series D funding round of $372 million as...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
- R&D
Sionna Therapeutics Targets $156 Million in IPO to Advance Cystic Fibrosis Research
Sionna Therapeutics, a biotechnology firm headquartered in Waltham, Massachusetts, is preparing to raise up to $156 million through an initial public offering (IPO) as...Oculis’ Phase 2 Study Explores OCS-05 for Optic Nerve Inflammation
A phase 2 clinical trial has assessed the effectiveness and safety of OCS-05, a peptidomimetic small molecule developed by Oculis, for patients with optic...Research finds Merck’s treatment of lung disease can lower chance of death
Mohsin Riaz - 0Merck has released that its drug, Winrevair, reduced the risk of death in patients suffering from a rare condition that causes high blood pressure...GSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval in Younger Adults
Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader...
- Clinical
Bristol Myers Cuts Off Allergy Asset In Spite of Phase 3 Victory
Bristol Myers Squibb has persisted with its aggressive cost-reduction strategy, abandoning plans to market a competitor to Dupixent despite achieving its phase 3 objectives...Leap Therapeutics Shifts Focus to Colorectal Cancer After Mixed Phase 2b Trial Results
Leap Therapeutics has decided to redirect its efforts towards colorectal cancer following mixed results from a midstage trial of its anti-DKK1 antibody, sirexatamab. The...InnoCare and Keymed License Ex-China Rights for Bispecific to RTW-Backed Biotech in $520M Agreement
Chinese biotechs InnoCare Pharma and KeyMed Biosciences have licensed the international rights for their clinical-stage bispecific antibody, ICP-B02 (also known as CM355), to Prolium...Disc Medicine Refines Trial Design for EPP Drug, Targets Accelerated FDA Approval
Disc Medicine has finalized the design for its confirmatory trial of bitopertin, a drug candidate aimed at addressing a rare blood disorder, erythropoietic protoporphyria...
- Commercial
Biogen Secures Ex-U.S. Rights to Dravet Syndrome Treatment
Biogen has bolstered its research and development efforts by securing an agreement with Stoke Therapeutics for the ex-U.S. rights to zorevunersen, a treatment candidate...Former Inizio Evoke Executives Launch Flex Marketing
A group of former executives from health communications firm Inizio Evoke have launched Flex Marketing, a new independent agency catering to pharmaceutical, biotech, medtech,...Abcuro Secures $200 Million to Advance Ulviprubart for Inclusion Body Myositis Treatment
Abcuro, a biotechnology company backed by Sanofi, has secured $200 million in Series C funding to advance its anti-KLRG1 antibody, ulviprubart, through a phase...
- Technology
Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...AI Firm Formation Bags $372 Series D Funding
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was able to secure a remarkable series D funding round of $372 million as...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
Editor Picks
Life Science Voice Top Five Newsletter – February 2023
This week take a look at a new, long-acting, adhesive for your...
Avillion and AstraZeneca combination medicine presents positive results for people living with asthma 
The New England Journal of Medicine has published the results of Avillion...
Gilead’s Trodelvy lung cancer trial fails to increase survival, leading to a sell-off
Gilead encountered a significant setback concerning its antibody-drug conjugate (ADC) Trodelvy. The...
Must Read
Life Sciences Voice Top Five Newsletter
Welcome to this week’s edition of the Life Sciences Voice Top Five Newsletter, your...
Biogen Secures Ex-U.S. Rights to Dravet Syndrome Treatment
Biogen has bolstered its research and development efforts by securing an agreement with Stoke...
FDA Approves Romvimza for Treatment of Tenosynovial Giant Cell Tumor
The U.S. Food and Drug Administration (FDA) has approved Romvimza (vimseltinib) for the treatment...
About Us
Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.
Contact us: reachout(at)lifescivoice.com